For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 0 | 8,553 | ||
| Research and development | 267,115 | 152,413 | ||
| General and administrative | 59,083 | 56,305 | ||
| Total operating expenses | 326,198 | 208,718 | ||
| Loss from operations | -326,198 | -200,165 | ||
| Other income, net | 22,930 | 17,346 | ||
| Total other income | 22,930 | 17,346 | ||
| Net loss | -303,268 | -182,819 | ||
| Basic EPS | -13.48 | -10.21 | ||
| Diluted EPS | -13.48 | -10.21 | ||
| Basic Average Shares | 22,504,676 | 17,906,794 | ||
| Diluted Average Shares | 22,504,676 | 17,906,794 | ||
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)